【摘要】：目的檢測miR-17-92簇成員分子(miR-17、miR-18a、miR-19a、miR-19b、miR-20a和miR-92a)在人乳頭瘤病毒(HPV)陽性宮頸癌(CC)及上皮內瘤變(CIN)患者血清中的表達水平,并評估其對HPV陽性宮頸癌的早期診斷價值。方法收集HPV陽性宮頸癌患者150例(CC組)、HPV陽性CIN1~3級患者100例(CIN組)及單純HPV陽性或子宮良性病變者150例(對照組)血清,采用實時定量PCR(RT-q PCR)法檢測血清中miR-17-92簇成員分子的表達,結合液基薄層細胞學檢測(TCT)結果,評價miR-17-92簇成員分子在HPV陽性宮頸癌中的早期診斷價值。結果與對照組相比,miR-18a和miR-92a在CC組血清中異常高表達,且其表達水平顯著高于CIN組及對照組,兩者在CIN3級患者中的表達水平及miR-18a在CIN1-2級患者中的表達水平均顯著高于對照組(P均0.05)。受試者工作曲線(ROC曲線)分析結果顯示,血清miR-18a診斷CIN3及CC(CIN3+)的曲線下面積(AUC)為0.792(95%CI:0.749~0.862),靈敏度為87%,特異度為65%;血清miR-92a診斷CIN3+的AUC為0.799(95%CI:0.744~0.847),靈敏度為55.8%,特異度為92%;TCT診斷CIN3+的AUC為0.645(95%CI:0.582~0.704),靈敏度為51.9%,特異度為77%。血清miR-18a和miR-92對宮頸癌和CIN3+的診斷效能均顯著優(yōu)于TCT檢測(P均0.01)。結論 miR-17-92簇成員分子miR-92a和miR-18a在HPV陽性宮頸癌患者血清中高表達,并可作為HPV陽性宮頸癌的早期診斷及鑒別高級別CIN的潛在標志物。
[Abstract]:Objective to detect the expression of miR-17-92 cluster members (miR-17,miR-18a,miR-19a,miR-19b,miR-20a and miR-92a) in the serum of patients with (HPV) positive cervical cancer (CC) and (CIN). To evaluate its value in early diagnosis of HPV positive cervical cancer. Methods Serum samples were collected from 150 patients with HPV positive cervical cancer (CC group, 100 cases of), HPV positive CIN1~3 grade patients (CIN group) and 150 cases of simple HPV positive or uterine benign lesions (control group). The expression of miR-17-92 cluster molecules in serum was detected by real-time quantitative PCR (RT-q PCR) method, and the results of (TCT) were detected by liquid-based thin layer cytology. To evaluate the value of miR-17-92 cluster molecules in early diagnosis of HPV positive cervical cancer. Results compared with the control group, the expression of miR-18a and miR-92a in serum of CC group was significantly higher than that of CIN group and control group. The expression levels of miR-18a and miR-18a in CIN3 patients and CIN1-2 patients were significantly higher than those in the control group (P < 0. 05). The results of ROC curve analysis showed that the area under the curve of serum miR-18a for the diagnosis of CIN3 and CC (CIN3) was 0.792 (95%CI:0.749~0.862), the sensitivity was 87, and the specificity was 65. The AUC of serum miR-92a for the diagnosis of CIN3 was 0.799 (95%CI:0.744~0.847), the sensitivity was 55.8 and the specificity was 92; The AUC of TCT for diagnosing CIN3 was 0.645 (95%CI:0.582~0.704), the sensitivity was 51.9 and the specificity was 77. The diagnostic efficacy of serum miR-18a and miR-92 in the diagnosis of cervical cancer and CIN3 was significantly better than that of TCT (P 0.01). Conclusion miR-92a and miR-18a are highly expressed in the serum of patients with HPV positive cervical cancer and can be used as a potential marker for early diagnosis and differential diagnosis of high grade CIN in patients with HPV positive cervical cancer.
【作者單位】： 山東大學齊魯醫(yī)院婦產科;平原縣第一人民醫(yī)院麻醉科;
【基金】：國家自然科學基金(81372808) 山東大學基本科研業(yè)務費(2082015QLMS44)
【分類號】：R737.33
，

本文編號：2361420